Thursday, January 2, 2014

Novocure: 18 certified doctors to prescribe the NovoTTF therapy in Europe and Israel

Tags

Novocure: 18 certified doctors to prescribe the NovoTTF therapy in Europe and Israel -

Novocure, a commercial stage oncology company, announced today that 18 neurosurgeons and prominent neuro-oncologists in medical centers in Europe and Israel are trained and certified to prescribe the NovoTTF therapy. These physicians will now be able to treat patients with recurrent glioblastoma using this novel anti-mitotic therapy on prescription control outside clinical trials

The following physicians were certified to treat patients using the NovoTTF therapy :.

Austria
Vienna
-Prof. Priv.-Doz. Dr. med. Mr. Preusser, Ordinationszentrum Döbling

Czech Republic
Prague
-Prof. Dr. med. J. Vymazal, Na Homolce Hospital

England
London
- Prof. Dr. med. C. Lindquist, Cromwell Hospital

France
Lyon
-Prof. J. Honnorat, Neurological Hospital, Hospices Civils de Lyon
Paris
-Dr. Ahmed Idbaih, Groupe Hospitalier Pitié Salpêtrière

Germany
Düsseldorf
-Prof. Dr. med. F. Ulrich, Neuro-Unit CME Düsseldorf
Duisburg
-Prof. Dr. med. Mr. Scholz and Prof. Dr. med. S. Petrasch, Klinikum Duisburg / Wedau Kliniken
Hamburg
-Dr. med. T. Martens and Prof. Dr. med. Mr. Westphal, Universitätsklinikum Hamburg-Eppendorf
Heidelberg
-Prof. Dr. med. W. Wick, Universitätsklinikum Heidelberg
Kiel
-Prof. Dr. med. H. Mr. Mehdorn, Universitätsklinikum Schleswig-Holstein
Regensburg
-Dr. med. Doenitz and Prof. C. Dr. med. A. Brawanski, Universitätsklinikum

Greece
Athens
-Dr. Mr. Torrens, CHM FRCS, Hospital HYGEIA

Israel
Tel Aviv
-Prof. Zvi Ram, Tel Aviv Medical Center

Switzerland
Lausanne
-Dr. med. A. Hottinger, MD PhD, Centre Hospitalier Universitaire Vaudois
Zurich
-Prof. Dr. med. R. Stupp, University Hospital Zurich

"We are honored to work with these experts world-renowned oncology to provide NovoTTF therapy for patients with recurrent glioblastoma," said Peter Melnyk, commercial director of Novocure . "The eminent training doctors of these clinics is the first step in the commercial launch of our product in Europe and Israel."


EmoticonEmoticon